Bicycle Therapeutics plc

DB:50BA Stock Report

Market Cap: €551.2m

Bicycle Therapeutics Management

Management criteria checks 3/4

Bicycle Therapeutics' CEO is Kevin Lee, appointed in Sep 2015, has a tenure of 9.67 years. total yearly compensation is $4.86M, comprised of 15.6% salary and 84.4% bonuses, including company stock and options. directly owns 0.4% of the company’s shares, worth €2.19M. The average tenure of the management team and the board of directors is 3.3 years and 5.8 years respectively.

Key information

Kevin Lee

Chief executive officer

US$4.9m

Total compensation

CEO salary percentage15.6%
CEO tenure9.7yrs
CEO ownership0.4%
Management average tenure3.3yrs
Board average tenure5.8yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Kevin Lee's remuneration changed compared to Bicycle Therapeutics's earnings?
DateTotal CompensationSalaryCompany Earnings
Mar 31 2025n/an/a

-US$203m

Dec 31 2024US$5mUS$760k

-US$169m

Sep 30 2024n/an/a

-US$166m

Jun 30 2024n/an/a

-US$165m

Mar 31 2024n/an/a

-US$168m

Dec 31 2023US$6mUS$710k

-US$181m

Sep 30 2023n/an/a

-US$162m

Jun 30 2023n/an/a

-US$140m

Mar 31 2023n/an/a

-US$124m

Dec 31 2022US$9mUS$673k

-US$113m

Sep 30 2022n/an/a

-US$101m

Jun 30 2022n/an/a

-US$87m

Mar 31 2022n/an/a

-US$78m

Dec 31 2021US$4mUS$677k

-US$67m

Sep 30 2021n/an/a

-US$66m

Jun 30 2021n/an/a

-US$62m

Mar 31 2021n/an/a

-US$56m

Dec 31 2020US$3mUS$592k

-US$51m

Sep 30 2020n/an/a

-US$38m

Jun 30 2020n/an/a

-US$37m

Mar 31 2020n/an/a

-US$35m

Dec 31 2019US$4mUS$517k

-US$31m

Sep 30 2019n/an/a

-US$33m

Jun 30 2019n/an/a

-US$31m

Mar 31 2019n/an/a

-US$26m

Dec 31 2018US$818kUS$386k

-US$22m

Compensation vs Market: Kevin's total compensation ($USD4.86M) is above average for companies of similar size in the German market ($USD1.21M).

Compensation vs Earnings: Kevin's compensation has been consistent with company performance over the past year.

CEO

Kevin Lee (56 yo)

9.7yrs

Tenure

US$4,857,218

Compensation

Dr. Kevin Lee, M.B.A., Ph D., has been Chief Executive Officer of Bicycle Therapeutics plc since September 2015. Dr. Lee joined Bicycle Therapeutics from Pfizer where he served as Senior Vice President and...

Leadership Team

NamePositionTenureCompensationOwnership
Kevin Lee
CEO & Executive Director9.7yrsUS$4.86m0.40%
€ 2.2m
Gregory Winter
Co-Founder & Non-Executive Directorno dataUS$327.72k0.25%
€ 1.4m
Alethia Young
Chief Financial Officer1.8yrsUS$1.47m0.0031%
€ 17.0k
Alistair Milnes
Chief Operating Officer3.3yrsUS$2.59m0.037%
€ 201.8k
Michael Hannay
Chief Product & Supply Chain Officer1.2yrsUS$2.37m0.0072%
€ 39.5k
Christian Heinis
Scientific Founderno datano datano data
Travis Thompson
Senior VP1.9yrsno data0.046%
€ 253.5k
Michael Skynner
Chief Technology Officer3.3yrsUS$3.07m0.083%
€ 455.2k
Stephanie Yao
Senior Vice President of Investor Relations and Corporate Communicationsno datano datano data
Zafar Qadir
Chief Legal Officer & General Counsel5.1yrsno datano data
Gillian Langford
Head of Clinical and Project Management9yrsno datano data
Phil Jeffrey
Senior VP of Pre-Clinical Development6.5yrsno datano data

3.3yrs

Average Tenure

55.5yo

Average Age

Experienced Management: 50BA's management team is considered experienced (3.3 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Kevin Lee
CEO & Executive Director9.7yrsUS$4.86m0.40%
€ 2.2m
Gregory Winter
Co-Founder & Non-Executive Directorno dataUS$327.72k0.25%
€ 1.4m
Keith Peters
Chairman of Scientific Advisory Board7yrsno datano data
Pierre Legault
Non-Executive Chairman6.2yrsUS$906.61k0.031%
€ 171.2k
Jose-Carlos Gutierrez-Ramos
Independent Non-Executive Director4.2yrsUS$342.18k0.016%
€ 85.6k
Richard Kender
Independent Non-Executive Director5.8yrsUS$374.60k0.016%
€ 85.6k
Garret FitzGerald
Member of Scientific Advisory Board4.6yrsno datano data
Caetano Reis e Sousa
Member of Scientific Advisory Board4.6yrsno datano data
Janice Bourque
Independent Non-Executive Director5.8yrsUS$343.44k0.016%
€ 85.6k
Geoffrey Shapiro
Member of Scientific Advisory Board7yrsno datano data
Charles Swanton
Member of Scientific Advisory Board4.6yrsno datano data
Jane Grogan
Member of Scientific Advisory Board4.6yrsno datano data

5.8yrs

Average Tenure

64yo

Average Age

Experienced Board: 50BA's board of directors are considered experienced (5.8 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/05/06 18:27
End of Day Share Price 2025/05/06 00:00
Earnings2025/03/31
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Bicycle Therapeutics plc is covered by 20 analysts. 13 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Peter LawsonBarclays
Kalpit PatelB. Riley Securities, Inc.
Arlinda LeeCanaccord Genuity